NuGEN and KeyGene Announce Settlement in Declaratory Judgment

Wageningen, Netherlands; San Carlos, CA, USA, Aug 13, 2018

Today NuGEN Technologies, Inc. and Keygene N.V. announced an agreement to settle a declaratory judgment lawsuit brought by NuGEN Technologies concerning KeyGene’s U.S. Patent Nos. 9,702,004, 9,745,627 and 9,896,721. Under the terms of the settlement, the lawsuit and counterclaims have been dismissed. Financial terms and other specifics of the settlement were not disclosed.

About NuGEN Technologies, Inc.

Based in San Carlos, California, NuGEN Technologies, Inc., provides innovative NGS and genomic sample prep products for a broad range of sample types including RNA and DNA from whole tissues, FFPE samples, single cells and liquid biopsies. NuGEN’s products offer rapid and simple workflows designed to reduce time and cost per sample. NuGEN products are used by 1000s of customers in basic research, applied markets and molecular diagnostics. NuGEN products are manufactured under stringent quality controls (ISO 13485). The Tecan Group recently acquired NuGEN Technologies, Inc. to further expand Tecan’s dedicated solutions offering into the new market segment of next-generation sequencing (NGS) reagents. To learn more about NuGEN visit www.nugen.com.

Media contact

NuGEN Technologies, Inc., media@nugen.com